

April 2021 PDL/DUR Board Meeting Minutes

Date: April 21, 2021

Members Present: King, Anglim, Blake, Blank, Brown, Caldwell, Jost, Maxwell, McGrane, Nauts, Stone

Members Absent: Putsch

Others Present: Peterson, Sexauer, Feist (DPHHS); Kathy Novack (Magellan); Artis, Bahny, Barnhill, Doppler, Opitz, Woodmansey (MPQH); Various representatives from the pharmaceutical industry.

Tony King introduced himself and opened the meeting.

Public Comment: A letter from several providers was sent to the board regarding Trulicity® (dulaglutide), requesting it be a preferred product. Tony informed the board that a decision to move Trulicity® (dulaglutide) to preferred status had already been made by the Department after the March PDL meeting and would be effective May 2021. No other public comment was presented.

Meeting Minute Review: The March meeting minutes were reviewed and approved as written.

Department Update: None

PREFERRED DRUG LIST MEETING

Results of the Board review of Group 3 (Red category):

CLASS	DRUG NAME	2021 RECOMMENDATIONS	Grandfathered
ANTIBIOTICS, GI	Vancocin®-NI	Must have metronidazole and vancomycin. May add others.	No
ANTIBIOTICS, VAGINAL	Vandazole®-NI	Therapeutic alternatives.	No
ANTIFUNGALS, TOPICAL	Jublia®-NI	Therapeutic alternatives for approved indications.	No
ANTIVIRALS, ORAL (HSV/INFLUENZA)	Xofluza®-NI	<u>HSV Antivirals</u> - Class effect. <u>INFLUENZA Antivirals</u> - Must have both oseltamivir and baloxavir marboxil.	No
CYTOKINES & CAM ANTAGONIST	Erelzi®, Hulio® -ND Arcalyst®, Cosentyx®, Ilaris®, Kineret®, Simponi®, Stelara®, Taltz®, Tremfya®, Xeljanz® -NI	Therapeutic alternatives; Do not add anakinra (Kineret®) due to inferior efficacy and increased toxicity. Grandfathered class.	Yes
GLUCOCORTICOIDS, INHALED	Breztri®-ND Trelegy®-NI	Class effect.	No

CLASS	DRUG NAME	2021 RECOMMENDATIONS	Grandfathered
GLUCOCORTICOIDS, ORAL	Alkindi Sprinkle®-ND	<u>SHORT ACTING</u> - cortisone, hydrocortisone - Therapeutic alternatives. <u>INTERMEDIATE ACTING</u> - methylprednisolone, prednisone, and prednisolone- Therapeutic alternatives, must include a dosepak. <u>LONG ACTING</u> - betamethasone, dexamethasone - Therapeutic alternatives. <u>BUDESONIDE</u> - Must have 1 budesonide. <u>Deflazacort</u> - May add, continue PA criteria.	No
HEPATITIS C AGENTS	Epclusa®-NI	<u>Ribavirins</u> - Class effect. <u>Pegylated interferons</u> -Do not add since these are no longer standard of care. <u>All others</u> - Therapeutic alternatives. Must have a pangenotypic agent. Continue with existing PA criteria. Grandfathered class.	Yes

CLASS	DRUG NAME	2021 RECOMMENDATIONS	Grandfathered
IMMUNOMODULATORS, ATOPIC DERMATITIS	Eucrisa®, Dupixent®-NI	Therapeutic alternatives. <i>Changed from class effect.</i> Continue PA criteria.	No
STERIODS, TOPICAL	Ultravate®-NI	<u>LOW, MEDIUM, HIGH and VERY HIGH POTENCY CLASSES</u> -Class effect for each class; must have 1 cream and 1 ointment from each category, may add other forms.	No

The Board reviewed the blue category in advance of the meeting. Kathy from Magellan reported on new generics and discontinued items in this category. This category of drugs has no new clinically significant information since last review. Board recommendations for Group 2 (Blue category) from 2020 were retained. They are as follows:

CLASS	2021 RECOMMENDATIONS	Grandfathered
ACNE AGENTS	<ul style="list-style-type: none"> • <u>Benzoyl Peroxide Combos</u> – Class effect. • <u>Benzoyl Peroxide Agents</u>– Class effect. • <u>Clindamycin Agents</u> – Class effect. • <u>Sodium Sulfacetamide Agents</u> – Class effect. • <u>Azelaic Acid</u> – May add. • <u>Dapsone topical</u> – May add. • <u>Topical Retinoids & Combos</u> – Class effect. • <u>Erythromycin topical</u> – Class effect. 	No
ANTI-ALLERGENS, ORAL	May add with clinical criteria.	No
ANTIBIOTICS, INHALED	Therapeutic alternatives.	No

CLASS	2021 RECOMMENDATIONS	Grandfathered
ANTIBIOTICS, TOPICAL	Must have a mupirocin product. <i>Removed, may have retapamulin, as this product is no longer available.</i>	No
ANTIFUNGALS, ORAL	Must have terbinafine and fluconazole. Must have 1 of clotrimazole or nystatin. Continue PA criteria on ketoconazole. <i>Removed may add others.</i>	No
ANTIHISTAMINES, MINIMALLY SEDATING	Class effect. Must have one single ingredient agent.	No
ANTINEOPLASTIC AGENTS, TOPICAL	Therapeutic alternatives.	No
ANTIPARASITICS, TOPICAL	Therapeutic alternatives. Continue PA criteria.	No
ANTIPSORIATICS, TOPICAL	Class effect. Must have one topical formulation and a scalp formulation. Continue PA criteria.	No
ANTIVIRALS, TOPICAL	Class effect.	No
BLADDER RELAXANTS	Class effect. Must have 1 long-acting agent (either by half-life or dosage form). May add Myrbetriq.	No
BPH AGENTS	<u>ALPHA BLOCKERS</u> - Class effect. <u>ANDROGEN HORMONE INHIBITORS/COMBOS</u> - Class effect. <u>PDE-5 for BPH</u> - tadalafil will be non-preferred. Continue with PA criteria.	No
BRONCHODILATORS, BETA AGONISTS	<u>Beta Agonist, Long Acting</u> - Class effect. <u>Beta Agonist, Short Acting</u> - Class effect.	No
CEPHALOSPORINS & RELATED AGENTS	<u>2nd Generation</u> - Class effect. <u>3rd Generation</u> - Class effect.	No
COPD AGENTS	Class effect. Must have a nebulizer product and a long-acting combination product.	No
EPINEPHRINE, SELF-INJECTED	Class effect.	No
FLUOROQUINOLONES, ORAL	<u>2nd Generation</u> - Class effect. Must have ciprofloxacin. <u>3rd Generation</u> - Class effect.	No
IMMUNOMODULATORS, TOPICAL	Class effect.	No
IMMUNOSUPPRESSANTS	Must have all chemical entities. Grandfathered class.	Yes

CLASS	2021 RECOMMENDATIONS	Grandfathered
INTRANASAL RHINITIS AGENTS	<u>Nasal Steroids</u> - Class effect. <u>Nasal Antihistamines & others</u> - Class effect.	No
LEUKOTRIENE MODIFIERS	Must have montelukast. May add zafirlukast.	No
MACROLIDES & KETOLIDES	Class effect. Must have azithromycin, clarithromycin and erythromycin.	No
METHOTREXATE AGENTS	Must have one oral and one injectable agent.	No
ROSACEA AGENTS, TOPICAL	Must have one metronidazole product. May add others.	No

CLASS	2021 RECOMMENDATIONS	Grandfathered
SMOKING CESSATION	Must have a nicotine patch and either nicotine gum or lozenge. Must have varenicline. May add others.	No
TETRACYCLINES	Must have doxycycline. May add others.	No

There were no Group 1 (green category) drugs to review.

Meeting adjourned at 2:48pm. The final PDL meeting for 2021 will be held on May 26th in this same format.